Stifel reiterated a Buy rating on Repare Therapeutics, saying that lunresertib plus camonsertib efficacy looks “encouraging.” The firm believes the negative stock reaction is probably more of a function of the tox profile.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RPTX: